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A B S T R A C TObjectives: Hospitals, physicians, payers, and patients face economic
and ethical decisions about the use of biotechnology drugs, com-
monly called specialty medications. These often target a small
population, have data based on smaller clinical trials, are expensive,
and may have questionable advantage. This is a result of how the
Food and Drug Administration (FDA) approves medications, which is
based only on safety and efficacy. Cancer drugs, once approved by the
FDA, regardless of cost or value must be covered by Medicare. Some
states have laws requiring additional coverage as well. All of this has
created an unintended consequence: It has driven up costs with
questionable evidence to support the medication’s value, placing
patients, payers, and providers in an ethical conflict. In this new
era of health care transformation, health care leaders must focus on
creating value to support a sustainable health system. Christiana
Care Health System’s Value Institute has designed a new model to
evaluate specialty medications, using value as its main criterion.
Methods: This article describes the process and outcomes using a
new value model for evaluating specialty medications for a hospital
formulary. It also introduces a new criterion of evaluation entitled
‘‘Societal Benefit’’ that provides a rating on quality- of-life issues.
With measurable factors of efficacy, risk, cost, and quality-of-lifesee front matter Copyright & 2013, International
r Inc.
.1016/j.jval.2013.03.1623
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dence to: Raymond J. Seigfried, Christiana Care Heaconcerns, our methodology provides a more balanced approach in
the evaluation of specialty medications. Results: Specialty medica-
tions are the fastest growing segment of drug expense, and it is hard
to understand how these medications will be sustainable under
health care reforms. Unlike other countries, the United States has
no national agency providing cost-effectiveness review; review
occurs, if at all, at a local level. Laws governing Medicare and most
private insurers’ coverage of FDA-approved medication and some
clinical quality standards conflict with cost-effectiveness, making
this type of review difficult. Finally, because these medications affect
the health system as a whole, it is a great example to begin to support
health care reform. Conclusions: Hospitals need to challenge the
value of specialty medication. Although our model will continue to
evolve, value is now our central consideration when selecting
specialty medications to be added to the formulary. We share this
experience to encourage other hospitals to design their own
approach to this vital issue.
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Recently, a new category of medications called specialty drugs has
emerged. These are very different from their forebears, both in
effectiveness and in cost. They are high tech and high cost and are
targeted at a very small percentage of patients, particularly in
oncology, and they account for a much larger share of the overall
cost. While many specialty drugs might slow the rate of disease or
alleviate symptoms, few cure the disease long-term. Moreover, they
can have severe or even fatal adverse effects and many have so-
called black-box warnings from the Food and Drug Administration
(FDA), or have manufacturer controls. Most of these medications
are considered expensive, with total treatment costs sometimes
exceeding $100,000 (with off-label use even higher) per patient.
The health care system has reacted to specialty drugs in a
very predictable way. Insurance companies respond by passing
on higher co-pays to the consumer. Twenty state governments
react to this public concern by introducing or passing legislation
limiting out-of-pocket payments for specialty medications.Insurance companies fear that by reducing payment by users,
they shift the burden of increasing rates for everyone else.
Physicians are confronted with quality standards that recom-
mend using specialty medications regardless of cost. Hospitals
shoulder the additional cost for these medications.
With ever more specialty drugs entering the market, it is
increasingly important for hospitals and specifically their Pharmacy
& Therapeutics (P&T) committees to develop an evidence-based and
societal value approach to selecting which of these products should
get onto the formulary. It might be argued that hospital-based
reviews are not needed because the FDA has already approved the
medication. In light of health care reform, hospital systems have no
choice but to select drugs that are effective and have value.Value Model
Christiana Care has assessed 12 of these medications by using a
new value process. The mix of medications (oncology,Society for Pharmacoeconomics and Outcomes Research (ISPOR).
lth System, 4755 Ogletown-Stanton Road, Newark, DE 19718, USA.
Table 1 – Efficacy assessment.
Components of efficacy assessment Score
(points)
Patient important outcome
Prevention or cure of disease 3
Improve function (slow disease, alleviate
symptoms)
2
End-of-life care 1
Medication tolerability
Tolerable
Evaluated medication as tolerable or more
tolerable than comparator
2
Incidence of discontinuation of evaluated
medication o10% (no comparator)
2
Low tolerability
Evaluated medication less tolerable than
comparator
0.5
Incidence of discontinuation of evaluated
medication Z10% (no comparator)
0.5
Level of evidence
Randomized trials assessing patient important
outcome
3
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 9 0 1 – 9 0 6902pulmonary, rheumatologic, and immunosuppressive) allowed us
to refine the process. Seven were approved by our P&T Commit-
tee and four were not. A final decision on one medication was
deferred until a therapeutic evaluation is completed. Had the
health system added all 12 medications to formulary, the annual
projected cost impact would have been greater than $21 million.
Our traditional method of evaluating a medication assessed
efficacy, safety, and cost. A clinical pharmacist developed a
monograph summarizing the available literature and provided
an estimate of annual cost based solely on acquisition cost and a
projection of the number of patients likely to utilize the medi-
cation within a year. The monograph, which concluded with the
clinical pharmacist’s recommendation, was then reviewed by a
physician who provided additional comments. The P&T Commit-
tee then decided whether the medication would or would not be
added to the health system formulary. This process was reason-
ably effective until about 2010, when several newer medications
reached the market and commanded considerably higher prices.
The rising costs led us to question whether our formulary process
was adequate or whether summarizing the available literature
without a framework for assessing value could lead to rising
costs with little or no improved outcomes.
We therefore formed a task force to establish a ‘‘value frame-
work.’’ It was led by the Administrator member on P&T with
representative members from the medical- dental staff, pharmacy,
nursing, and finance. After reviewing the literature and existing
structures for grading levels of evidence, the four criteria we selected
were efficacy, risk, cost, and societal benefit. Each medication would
be reviewed against an equivalent medication or alternative therapy.
In the event none existed, the medication would stand on its own
merits. With the criteria determined, the P&T Committee estab-
lished a Medication Value Subcommittee chaired by a physician and
withmembers from administration, pharmacy, nursing, and finance.
The subcommittee decided upon a scorecard format. Assigning
numerical values to the criteria allowed us to stratify variables
among medications. This is especially useful when there are
alternative medications to compare. While scoring a medication
across the four criteria allows for easier comparison of therapies,
we did not want to predetermine the P&T Committee’s final
decision. The scores merely inform the committee’s final decision.
A physician reviews the monograph and, as with our traditional
process, provides comments. The scoring and supporting informa-
tion for efficacy, risk, and cost are presented to our Societal Benefit
Team, which adds the score and commentary for that criterion.
With the scorecard for all four criteria complete, the enhanced
monograph is considered and discussed by the Medication Value
Subcommittee. The subcommittee in turn makes a formal recom-
mendation to the P&T Committee, which then makes the final
decision on the medication’s formulary status.
The P&T Committee is a standing hospital committee with 25
members representing our medical-dental staff, major specialties,
pharmacy, nursing, finance, administration, and risk management.
Over the last several years, the membership has had little turnover
and has developed an effective interprofessional team approach in
its review, dialogue, and decision making. Members speak openly
and honestly during deliberation and the leadership of the com-
mittee chair, a physician, has been invaluable to this cohesion.Well done observational studies assessing patient
important outcome
2
Other observational studies, expert opinion,
unsystematic observations
1
Outcome duration
43 y 3
1–3 y 2
3 mo too1 y 1
o3 mo 0Efficacy
The efficacy portion of the value assessment has four domains:
the outcomes reported in published studies, medication toler-
ability, the level of evidence for the observed outcomes, and the
duration of the reported outcomes (Table 1). The P&T Committee
decided to give efficacy the most weight in assessing medication
value. This is consistent with the FDA decision to approve amedication on the basis of a favorable benefit-to-risk assessment,
and avoids cost being given undue weight in the evaluation.
The categories of patient important outcomes are preventing
disease, curing disease, improving ability to function by slowing
disease progression or alleviating disease symptoms, and symp-
tom palliation at the end of life. These outcomes are ranked and
scored empirically. Medications that prevent or cure disease are
given the most weight. Ranking last are those medications that
relieve symptoms without improving ability to function, but this
does not suggest that the positive effect that symptom relief has
on quality of life is not valued.
After initial experience with the assessment process, we
decided to include a qualitative measure of a medication’s
tolerability. Tolerability is evaluated in relation to the medication
to which it is being compared. When no comparison is available,
the medication is considered tolerable if fewer than 10% of the
patients discontinued treatment because of adverse events.
Medications less tolerable than the comparator or that were
discontinued because of adverse effects by greater than or equal
to 10% of the patients are scored lower than better-tolerated
medications, as explained in the table. Tolerability is incorpo-
rated into the assessment process as a weighting factor. We
recognized that a medication that is not tolerated well might not
be preferred to an alternative, better-tolerated treatment.
One of the principles of evidence-based medicine is that there
is a hierarchy of evidence that guides decisions about treatments
[1]. At the top of the hierarchy is the randomized, double blind,
placebo controlled trial, followed by systematic reviews of
randomized trials and single randomized trials; at the bottom
are unsystematic clinical observations. In between are observa-
tional studies and clinical studies that report surrogate out-
comes. Stronger inferences about the efficacy of a treatment
Table 2 – Risk Assessment Checklist.
Item Point
value
1. The ordering and prescribing of this medication
is restricted by an Food and Drug Administra-
tion mandate or manufacturer controls.
26
2. The labeling for this medication includes a
black-box waming.
15
3. Historic Christiana Care experience with similar
medications suggests there would be safetly
concerns if the medication was approved for
formulary addition.
10
4. This medication falls within the category of ‘‘
high alert medication’’ as defined by
10
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 9 0 1 – 9 0 6 903can be drawn from randomized controlled trials, while system-
atic reviews can help develop valuable hypotheses that form the
basis for future clinical studies, while conclusions drawn solely
from clinical observations or nonrandomized data must be
viewed cautiously. Therefore, the level of evidence is scored
and stratified into three levels (strong, moderate, and weak) on
the basis of the type and strength of evidence available as part of
the efficacy assessment.
Duration of the reported outcome is the third domain. There
are four levels of duration of effect as described in the table.
These were defined to stratify survival benefit associated princi-
pally with oncologic medications. It may be necessary to refine
the characterization of outcome duration as experience is
acquired with other categories of medications. Efficacy, therefore,
contributes substantially to the total medication value score, as
the P&T Committee intended.Christiana Care policy.
5. This medication is dosed in a manner that
increases the potential for error (e.g. weight-
based dosing, titrated to effect, titrated in
response to lab results, dosed in micrograms,
etc.).
5
6. The drug interaction profile includes
contraindications or major severity drug
interactions with other medications currently
utilized at Christiana Care.
3
7. There is potential for a look-alike/sound-alike
medication error.
3
8. Use of this medication requires ongoing
laboratory monitoring for early detection of
specific side effects.
3
9. This medication been commercially available in
the United States for less than 1 year.
2
10. There are recommendations for dosing in
‘‘special populations’’ (e.g., neonates,
adolescents, elderly, renal impairment and
hepatic impairment).
2
11. The medication comes in a ready-to-use dosage
form.
2
12. This medication presents documented safety
concerns when used by breast-feeding or
pregnant patients.
1
13. There are special considerations for timing the
administration of this agent (e.g., food,
antacids and tube feedings)?
1
14. There are other safety considerations identified
during the review of this medication.
1Risk
Assessing and balancing risk versus benefit is a cornerstone of
decision making in patient care. It is, we believe, essential to include
this concept within objective criteria-based methods for assessing
the value of a medication in our practice setting. It is important to
include risk as a stand-alone category because a) when balancing
risk with benefit, numerous factors influence the level of risk
tolerability in any given scenario or a specific patient population
[2], and b) there are aspects of the risk assessment andmanagement
of higher-risk medications that cannot be appreciated within the
context of a clinical efficacy and side-effect profile review alone.
Clinical trials and evidence reviews focus primarily on two
aspects: 1) the efficacy of a medication in treating a specific disease
state and 2) the safety profile of a medication as it relates to drug
interactions, side effects, adverse effects, and tolerability. The FDA
addresses additional hazards to the patient beyond routine clinical
efficacy and safety assessment in the form of black-box warnings,
Risk Evaluation and Mitigation Strategies, recalls, safety alerts,
newsletters, and other methods. In addition, national medication
safety advocate organizations (e.g., Institute for Safe Medication
Practices) have identified specific hazards associated with medica-
tion use that increase the risk of an adverse drug event occurring,
reaching a patient, and resulting in harm. We developed a Risk
Assessment Checklist containing all these characteristics and
assigned a relative-risk point value to each (Table 2). We reviewed
the Risk Assessment Checklist for each medication, and the point
value is totaled. We created a range scale to categorize a medication
as low, moderate, or high risk from the Risk Assessment Checklist
point score. Each relative-risk category is assigned a point value that
contributes to a portion of the overall value score. For example, a
medication with a high risk has a value score of 1.
The Risk Assessment Checklist point value range was
designed to be rather wide so as to weight individual items
differently in relation to others on the basis of our own percep-
tions of risk. From the beginning there was much discussion over
item 11 (The medication comes in a ready-to-use dosage form). It
was designed with a negative point value as a way to account for
the advantage of drugs that come in a ready-to-use dosage form
and do not require further manipulation (e.g., unit-dose solid
forms, or premix infusion).Cost
Assessment begins with projecting the number of patients likely to
be eligible for the medication over a period of a year. The clinical
pharmacist notes the indications for which the medication is being
considered and works with the manager of clinical documentationto develop a list of diagnoses related to the indication. The resulting
diagnosis codes are passed to our Data Acquisition and Measure-
ment team. Members of that department in turn provide our
Finance Department with the number of patients coded with the
corresponding diagnoses within the previous year as well as the
payer mix across that group. Finance uses this information, coupled
with acquisition cost data provided by Pharmacy Services, to project
the net financial impact on the health system. If the medication
under consideration also requires laboratory monitoring, Risk
Evaluation and Mitigation Strategies program cost, or other cost,
Finance also receives this information to include in the assessment.
A score of 1 to 3 is assigned on the basis of the results.Societal Benefit
The decision to make a panel of community members a part of
medication value is the most controversial component of our
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ment of efficacy, risk, and cost but muchmore difficult to see how
opinions from members of our community have meaning in this
model. Community members who are not a part of the health
care system normally do not have the scientific knowledge
needed to determine a medication’s effectiveness. There is no
question that medication effectiveness is a critical component to
appropriate care and if our health care system were not in a state
of unsustainable cost and at times questionable outcomes,
effectiveness alone as a measure of value would be sufficient. It
is the reality of scarce resources and at times questionable
outcomes that elevates the voice of society. It is society as a
whole that determines our national health care direction and the
resources to sustain it through government policy. On the one
hand, we advocate for each patient to experience whatever care
is possible, and on the other hand, on a societal level we seek
care that is cost-effective. This conflict is seldom discussed,
let alone resolved. Physicians and providers tend to see health
care one patient at a time, but payers and government focus on
the total cost of that intervention. Both sides have meaningful
points, but these need to be understood as two parts of one
whole. A way of confronting this conflict is not by selecting one
side over the other but by focusing on the relationship between
these two views to make the system sustainable. So, when we
designed our value model, it incorporated both the effectiveness
of care and the voice of our community as a balanced view.
In forming this panel we had several concerns. Could a small
panel of five local community members reflect the general beliefs
of the community as a whole? What we found is that no group no
matter how large or small can truly represent the community as
a whole but with such a group we would obtain at least a sense of
community value. This led us to select a broad range of members
from the community. Another concern was that this group might
view all new and exciting drugs as desirable. The panel, however,
found 4 of the 12 reviewed medications to have low value to
society, which was an unexpected result.
The panel consists of two university professors, a local high
school teacher, a pastor, and a community activist. One of the first
things we had them do was to define the term ‘‘societal benefit.’’Table 3 – Value scorecard.
Value Criterion Efficacy ¼ (Outcome x
Tolerability) þ Duration þ
Evidence (minimum ¼ 1.5;
maximum ¼ 12)
Outcome (minimum ¼ 1;
maximum ¼ 3)
Comments
Tolerability (minimum ¼0.5;
maximum ¼ 2)
Comments
Evidence (minimum ¼ 1;
maximum ¼ 3)
Comments
Duration(minimum ¼ 0;
maximum ¼ 3)
Comments
Total
Overall Score
Recommendation of the Value Committee
Total Medication
High Value ¼
Moderate Value
Low Value ¼Their resulting definition revolves around two main principles.
First, that societal benefit is linked to improving quality of life.
And, second, that there should be sustained benefit to both the
community and the institution. The important part of this
definition is the concept of ‘‘improves quality of life.’’ They define
their role in the value process on the basis of their perception of
outcome. What they are saying is that medication value is defined
not by quality of care but from how medications contribute to a
patient’s quality of life. Their value score is provided after the
pharmacist and the physician provide background material on the
medication, and explain the measurement of efficacy, risk, and
cost results for the medication in question. This information is
presented to the Societal Benefit Panel for their knowledge and
questioning. On the basis of this information, the panel provides a
community sense of value or how the medication contributes to a
patient’s ‘‘quality of life’’ by rating the medication low, moderate,
or high with a score of 1, 2, or 3. In addition, they provide a
narrative of their score and why they rated the medication the
way they did. This score will then be added to the medication
model for an overall score of low, moderate, or high.
Once all the component parts of the model are
completed—efficacy, risk, cost, and social benefit—the subcom-
mittee meets to review the findings. It reviews each individual part
and corresponding score with the objective of reaching an overall
recommendation (Table 3). After our review of the metrics and the
narrative notes, the subcommittee produces a final recommenda-
tion. This recommendation goes to the next P&T Committee for a
final vote. Our assessment does not make a medication available
to select patients on the basis of who is paying the bill.Outcome
Christiana Care has now assessed 12 medications by using the
new value process. Another medication that was a candidate for
this process was withdrawn from consideration when the physi-
cian group that requested its addition to the health system
formulary was unable to come to consensus on the patient
population for which it would be prescribed. Four of theRisk
(minimum ¼ 1;
maximum ¼ 3)
Cost
(minimum ¼ 1;
maximum ¼ 3)
Societal Benefit
(minimum ¼ 1;
maximum ¼ 3)
Value Score:
16 – 21
¼ 10.5 – 15.5
4.5 – 10
Table 4 – Comparison of the scorecards for medi-
cations A and B.
Value Criterion Medication A Medication B
Efficacy High Moderate
Risk Moderate High
Net cost Neutral Unfavorable
Societal benefit High Low
Overall value High Low
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nal antibodies approved for different indications. The other
medications were an immunosuppressant, an antidote, a local
anesthetic, and an intravenous analgesic. One was requested for
an unlabeled indication. The average medication cost for an
episode (e.g., cycle of chemotherapy) of treatment in this group
was $17,699 (median $8,305, range $45–$94,500).
Two examples illustrate how the value model was applied to
evaluating medications. Medication A is an expensive antidote
that the P&T Committee added to the health system formulary.
Medication B is a medication used to treat a cancer for which
there is no really effective therapy for advanced disease. The P&T
Committee decided not to add medication B to the formulary.
Table 4 compares the scorecard for the two medications.
The efficacy of medication A was assessed on the basis of
three single-arm trials that evaluated its ability to prevent
toxicity by using a surrogate end point, a rapid and clinically
meaningful decline in the plasma concentration of the medica-
tion for which it is an antidote. The nature of the indication for
medication A does not permit a randomized controlled trial that
compares it with another antidote or placebo. Nonetheless, the
efficacy of medication A was rated high because of the nature of
the clinical outcomes medication A is expected to prevent, and
because it is tolerated relatively well. There is an established
relationship between the toxicity and the plasma concentration
of the medication for which medication A is an antidote.
However, the efficacy of medication B was rated moderate
because it was assessed on the basis of results of two randomized
controlled trials comparing the effect of medication B and an
alternative treatment on overall survival, and the mean absolute
effect of the medication was less than 4 months. In addition,
medication B caused serious adverse reactions in a significant
proportion of patients. Its labeling contains a black-box warning
about the possibility of treatment-related mortality.
When the Societal Benefit Panel evaluated the information on
the efficacy, tolerability, safety, and financial cost of medications
A and B to the health system, it concluded that medication A
provided relatively more benefit to the community or a higher
quality of life than did medication B. The Medication Value
Subcommittee agreed with the Societal Benefit Panel’s assess-
ment. Therefore, the overall value of medication Awas perceived
to be high and that of medication B to be relatively low.
The average medication value and societal benefit scores of
the medications evaluated to date were 13.5 (range 9–18) and 2.3
(range 1–3), respectively. Four medications were perceived to be of
high value, five of moderate value, and three of low value. The
Societal Benefit Panel agreed with the high value rating in all
instances and the low value rating in two of the three instances.
In the third instance, the panel perceived the medication to be of
moderate value. Overall, the sum of the efficacy and risk scores
and the societal benefit score among the 12 medications eval-
uated were not correlated (r ¼ 0.5058, P ¼ 0.093).
There appears, however, to be a relationship between the overall
value score and the P&T Committee decision. The P&T Committee
decided to add seven of the medications perceived to be of moderateto high value (total value scores 12.5–18) to the health system
formulary. Three of the medications were added without restriction.
The administration of the other four was limited to physician office
practices or an ambulatory infusion center. In one instance, the P&T
Committee decided to compare the effectiveness of the oral and
injectable formulations, and the impact on length of stay and patient
satisfaction among the patient population for which the injection
would be prescribed, before making a final decision. Four medications
(total value scores 9–14) were not added to the formulary because the
P&T Committee perceived them to be of relatively low value com-
pared with formulary alternatives, even though one of the medica-
tions was scored to be of high value. The discrepancy between the
P&T Committee’s decision not to add a medication to the formulary
and the value rating for the medication was due to a difference in its
perceived value between the Societal Benefit Panel and the P&T
Committee. The Societal Benefit Panel gave the medication its highest
value rating on the basis of results of efficacy, safety, and cost and how
these contributed to their belief in quality of life. While the P&T
Committee did not disagree with the Societal Benefit Panel on these
attributes of the medication, the P&T Committee’s perception of the
medication’s value was tempered by its relatively high cost and the
availability of less expensive alternatives on the formulary.
The other three medications the P&T Committee did not add
to the health system formulary were antineoplastics. The med-
ical oncologists and hematologists initially pushed back against
the value assessment process because they disagreed with these
decisions. Their discussions resulted in the subcommittee incor-
porating additional input from the physicians who request the
medications at each step in the assessment process to ensure
that their point of view is considered.
We have learned much as the health system has gained
experience with the value assessment model. First, as mentioned
above, it is important for the process to be transparent and
inclusive. Everyone must understand the methodology of the
value model. In addition, there must be open communication
between those requesting the addition of medications to the
formulary and those assessing the medications. Second, it is
difficult for physicians to consider the value of medications from
a population perspective when advocating for an individual
patient. This apparent conflict in perspectives, together with
the high costs of medications and payer medication reimburse-
ment policies, has set the stage for value review.
A third lesson has been from the physicians’ reaction to the
need to provide medication value decisions for formulary appro-
val. While most physicians agree that a value assessment is wise,
there is disagreement on whether it needs to exist at the health
system level. There are some who view FDA approval as evidence
that the medication has value. There are others who believe that
FDA approval alone is inadequate but that value assessments
need to occur at the national level and not so close to home. Still
others support conducting a value assessment at the health
system level but believe that the system cannot adequately reflect
the patient’s voice when it comes to defining value. Even though
our process does not include measuring patient perceptions, if the
health system, through a decision of P&T, decides not to make a
medication available it will work with the patient to find some
provider who will administer the medication. Another concern
physicians raise is that it does not incorporate quality standards
such as grade 1 recommendations and national guidelines for
managing a particular disease state. Adhering to national guide-
lines is frequently used as a benchmark of quality. Deciding that a
medication will not be available at the health system based on
value model causes alarm for physicians who fear that they will
be viewed as conducting practices of substandard quality.
This value model complements the more established
approaches to economic evaluation and decision making in health
care. As with other models, the approach can be adapted for use
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 9 0 1 – 9 0 6906in other areas. Although the health system continues to work to
gain broader physician support for the assessment process, the
organization as a whole supports the application of the value
concept in evaluating medications. These characteristics suggest
that the model could be scaled up for application in other areas.
The health system’s experience with the model to date is
limited. It does not yet have data on how its formulary decisions
have affected physicians’ approaches to treatment, patients’
behavior, the social and financial impact on patients, or the
financial impact on the institution. There was concern that
patients may transfer their care to another provider if a medica-
tion the health system deemed to be of relatively low value
was unavailable. Thus far this has not occurred, and patients
have not complained to the health system. As the health system
goes forward with its medication value model, it is desirableto incorporate patient-centric shared decision making into
the model.
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